India's Venus Seeks U.S. Partner For New Antibiotic Against Resistance
This article was originally published in PharmAsia News
Executive Summary
India's Venus Remedies said it wants to team with U.S.-based drug firm to develop and market Elores, an antibiotic adjuvant targeting pathogens that foster resistance.
You may also be interested in...
Largest PBMs Eliminate Consumers’ Cost Sharing For Opill On Most Commercial Plans
Decisions by “big three” PBMs suggest they’re taking proactive steps to comply with potential HRSA rulemaking to require most health plans, under Affordable Care Act regulations, to cover Opill and other types of OTC birth control without cost sharing.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.
Can Organovo Leverage Its Solid Phase II Data In MASH?
Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.